Tisagenlecleucel vs Standard of Care as Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III BELINDA Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [1] Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
    Bishop, Michael R.
    Dickinson, Michael
    Purtill, Duncan
    Barba, Pere
    Santoro, Armando
    Hamad, Nada
    Kato, Koji
    Sureda, Anna
    Greil, Richard
    Thieblemont, Catherine
    Morschhauser, Franck
    Janz, Martin
    Flinn, Ian W.
    Rabitsch, Werner
    Kwong, Yok Lam
    Kersten, Marie Jose
    Minnema, Monique C.
    Holte, Harald
    Chan, Esther Hian Li
    Martinez-Lopez, Joaquin
    Mueller, Antonia M. S.
    Maziarz, Richard T.
    McGuirk, Joseph P.
    Bachy, Emmanuel
    Le Gouill, Steven
    Dreyling, Martin
    Harigae, Hideo
    Bond, David A.
    Andreadis, Charalambos
    McSweeney, Peter A.
    Kharfan-Dabaja, Mohamed A.
    Newsome, Simon
    Degtyarev, Evgeny
    Del Corral, Chris
    Andreola, Giovanna
    Masood, Aisha
    Schuster, Stephen J.
    Jaeger, Ulrich
    Borchmann, Peter
    Westin, Jason R.
    BLOOD, 2021, 138
  • [2] BELINDA: A Phase 3 Study Evaluating the Safety and Efficacy of Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Westin, Jason
    Bishop, Michael
    Flinn, Ian
    Borchmann, Peter
    Jaeger, Ulrich
    Gu, Jessie
    Andreola, Giovanna
    Pacaud, Lida
    Schuster, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S270 - S271
  • [3] BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Bishop, Michael
    Flinn, Ian
    Borchmann, Peter
    Jaeger, Ulrich
    Westin, Jason
    Hamad, Nada
    Purtill, Duncan
    Greil, Richard
    Thomas, Simone
    Teshima, Takanori
    Harigae, Hideo
    Garcia, Carlos
    Barba, Pere
    Deol, Abhinav
    Shaughnessy, Paul
    Gu, Jessie
    Andreola, Giovanna
    Prieto, Marcela Martinez
    Pacaud, Lida
    Schuster, Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
    Bishop, M. R.
    Dickinson, M.
    Purtill, D.
    Barba, P.
    Santoro, A.
    Hamad, N.
    Kato, K.
    Sureda, A.
    Greil, R.
    Thieblemont, C.
    Morschhauser, F.
    Janz, M.
    Flinn, I
    Rabitsch, W.
    Kwong, Y-L
    Kersten, M. J.
    Minnema, M. C.
    Holte, H.
    Chan, E. H. L.
    Martinez-Lopez, J.
    Mueller, A. M. S.
    Maziarz, R. T.
    McGuirk, J. P.
    Bachy, E.
    Le Gouill, S.
    Dreyling, M.
    Harigae, H.
    Bond, D.
    Andreadis, C.
    McSweeney, P.
    Kharfan-Dabaja, M.
    Newsome, S.
    Degtyarev, E.
    Awasthi, R.
    del Corral, C.
    Andreola, G.
    Masood, A.
    Schuster, S. J.
    Jaeger, U.
    Borchmann, P.
    Westin, J. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07): : 629 - 639
  • [5] Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma
    Moleti, Maria L.
    Testi, Anna M.
    Foa, Robin
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) : 826 - 843
  • [6] Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Coyle, Luke
    Morley, Nicholas J.
    Rambaldi, Alessandro
    Mason, Kylie D.
    Verhoef, Gregor
    Furness, Caroline L.
    Zhang, Alicia
    Jung, A. Scott
    Cohan, David
    Franklin, Janet L.
    LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2103 - 2112
  • [7] Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Coyle, Luke
    Morley, Nicholas J.
    Rambaldi, Alessandro
    Mason, Kylie D.
    Verhoef, Gregor
    Furness, Caroline
    Zhang, Alicia
    Jung, A. Scott
    Franklin, Janet L.
    BLOOD, 2018, 132
  • [8] Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Coyle, Luke
    Morley, Nicholas J.
    Rambaldi, Alessandro
    Mason, Kylie D.
    Verhoef, Gregor
    Furness, Caroline
    Desai, Rajendra
    Mergen, Noemi
    BLOOD, 2020, 136
  • [9] Improving second-line therapy in aggressive non-Hodgkin's lymphoma
    Gisselbrecht, C
    Mounier, N
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 12 - 16
  • [10] TIGER-CTL019 phase II trial of Tisagenlecleucel in elderly patients with first-relapsed or primary refractory aggressive B-cell Non-Hodgkin Lymphoma
    Lohneis, A.
    Goedel, P.
    Balke-Want, H.
    Kutsch, N.
    Herling, C.
    Goergen, H.
    Leuchte, K.
    Borchmann, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 195 - 195
12345